October 20, 2005Open Access

Trastuzumab after Adjuvant Chemotherapy in HER2-Positive Breast Cancer

Key Points

Key points are not available for this paper at this time.

Abstract

One year of treatment with trastuzumab after adjuvant chemotherapy significantly improves disease-free survival among women with HER2-positive breast cancer. (ClinicalTrials.gov number, NCT00045032.)

Read Full Paperexternally

AI에게 질문

Bookmark

View Full Paper

Cite This Study

Piccart et al. (Thu,) studied this question.

synapsesocial.com/papers/69d7b52fb843b2be99490759 https://doi.org/https://doi.org/10.1056/nejmoa052306

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Phase II Study of Efficacy, Safety, and Pharmacokinetics of Trastuzumab Monotherapy Administered on a 3-Weekly Schedule2005 · 426 citations
2What Can We Learn from Herceptin<sup>®</sup> Trials in Metastatic Breast Cancer?2002 · 40 citations
3Phase II study of weekly intravenous recombinant humanized anti-p185HER2 monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer.1996 · 1,402 citations
4Remission of human breast cancer xenografts on therapy with humanized monoclonal antibody to HER-2 receptor and DNA-reactive drugs1998 · 388 citations
5Discrete sequential boundaries for clinical trials1983 · 1,740 citations

AI에게 질문

Bookmark

View Full Paper